Compare FENG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | MIRA |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 33.7M |
| IPO Year | 2011 | 2023 |
| Metric | FENG | MIRA |
|---|---|---|
| Price | $1.93 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.3K | ★ 198.7K |
| Earning Date | 03-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $106,947,410.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.17 | N/A |
| 52 Week Low | $1.28 | $0.73 |
| 52 Week High | $3.65 | $2.45 |
| Indicator | FENG | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 47.62 |
| Support Level | $1.80 | $1.45 |
| Resistance Level | $1.93 | $1.54 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 74.36 | 30.00 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.